The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: HIV

Friday Science Review: April 9, 2010

New fixes for diabetes, HIV, and nerve damage… Nano-Vaccine Cures Diabetes: To prevent the immune system from attacking pancreatic cells in Type 1 diabetes, a nanotechnology based “vaccine” was used successfully to stop the disease in mice.  The strategy involves nanoparticles that are coated with diabetes specific peptides and bound to MHC molecules. When injected [...]

Friday Science Review: March 12, 2010

Good viruses, bad viruses, biomarkers and protein structures in this week’s research highlights… Biomarker for Hodgkin’s Lymphoma Subset: Using a high-throughput genomic approach to associate gene expression profile with treatment outcomes for Hodgkin lymphoma, researchers identified an overexpression of genes typically expressed by macrophages in samples from patients who had experienced a relapse after treatment.  [...]

Friday Science Review: February 26, 2010

A few medical research applications this week… Personalized Medicine – for Lung Cancer: To develop a personalized medicine approach to treating non-small cell lung cancer (NSCLC), researchers generated a xenograft model where they implant human tumour tissue into the renal capsule of a host mouse.  As the tumour establishes itself, the mouse then becomes the [...]

No Company is an Island: More Pharma and Biotech Collaboration

Two deals this week showcase collaborative efforts between major pharma players:     Gilead Sciences Inc. entered a partnership with Tibotec Pharmaceuticals, a unit of J&J, to develop a single daily antiretroviral HIV pill combining Gilead’s Truvada with a drug Tibotec is developing called TMC278.  Gilead will take the lead in manufacturing and testing the combined drug, [...]

Novel Deal Structures Becoming More Common

At the RIC/OCETA talk I participated in last month, one of the trends in deal-making that I mentioned was novel structures.  At the time, examples included option deals and new ways to split rights and territories.  More recently, we’ve seen GSK and Pfizer form a joint venture to develop HIV treatments, and two more interesting ideas [...]

IVB’s Great Take on the GSK-Pfizer HIV Joint Venture

The In Vivo Blog has a really interesting post by Roger Longman discussing what they view as the groundbreaking and innovative aspects of GSK and Pfizer’s HIV joint venture, announced just over a month ago.  The gist is: The venture allows flexibility and accountability in an R&D operation with pharma-scale resources; and The JV has its [...]

Wednesday Brain Dump: March 4, 2009

Monkey Business: glycerol monolaurate (GML), a well-known microbicide, may protect macaques against SIV; but future experiments may need to use a modified HIV strain instead; meanwhile, who will protect them from the University of Louisiana?  Smoky Business: the tobacco industry is facing new litigation in Ontario, and FDA regulation in the U.S. Actual, Honest-to-Goodness* Profitable [...]

Follow

Get every new post delivered to your Inbox.

Join 93 other followers